<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48555">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474108</url>
  </required_header>
  <id_info>
    <org_study_id>SPAF</org_study_id>
    <nct_id>NCT02474108</nct_id>
  </id_info>
  <brief_title>Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion and Left Atrium Enlargement</brief_title>
  <official_title>Pilot, Randomized,Single Blind Trial of Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficiency of surgical prevention of atrial fibrillation
      in patients with valvular heart disease and left atrium enlargement
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preservation or appearance of AF(atrial fibrillation) after mitral valve surgery
      substantially reduce the number of excellent and good results of the operation in the
      long-term period, causing circulatory insufficiency, increased pulmonary hypertension,
      increasing the risk of thromboembolic events and stroke.

      Significant predictors of AF after surgery are the initial size of the left atrium more than
      6.0 cm, stenotic lesions and rheumatic genesis of mitral defect. 80% of patients in this
      group had AF during the first year after operation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite outcome measure of complications</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with freedom from AF according to the long-term ECG monitoring</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transport function of the left atrium according to TTE (transthoracic echo)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Rheumatic Heart Disease</condition>
  <arm_group>
    <arm_group_label>without prevention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>isolated mitral valve replacement or reconstruction, implantation of cardiac monitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group of prevention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mitral valve replacement or reconstruction with surgical prevention of AF (concomitant ablation of the left atrium) and implantation of cardiac monitor.
Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical prevention of atrial fibrillation</intervention_name>
    <description>Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.</description>
    <arm_group_label>group of prevention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cardiomonitor</intervention_name>
    <description>in both groups cardiac rhythm will be controlled by a cardiomonitor</description>
    <arm_group_label>without prevention</arm_group_label>
    <arm_group_label>group of prevention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  rheumatic mitral valve lesion

          -  the absence a history of AF

          -  sinus rhythm

          -  left atrium size more than 6.0 cm

        Exclusion Criteria:

          -  refusal to participate in the study

          -  aortic stenosis / regurgitation

          -  coronary atherosclerosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrey Sapegin</last_name>
    <phone>+79231821988</phone>
    <email>sapegin43@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Bogachev-Prokophiev</last_name>
    <phone>+79137539546</phone>
    <email>bogachev.prokophiev@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MeshalkinRI</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Sapegin</last_name>
      <phone>+79231821988</phone>
      <email>sapegin43@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrey Sapegin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Bogachev-Prokophiev</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 15, 2016</lastchanged_date>
  <firstreceived_date>April 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>prevention of AF</keyword>
  <keyword>mitral valve</keyword>
  <keyword>left atrium enlargement</keyword>
  <keyword>cryoablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Rheumatic Heart Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
